OBIONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Orchestra BioMed Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.65+0.20 (+3.67%)
Close on Oct 19, 2026
- Market cap
- $360.54M
- P/E (TTM)
- –
- Dividend yield
- –
Orchestra BioMed Holdings, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Partnership revenue | $32.87M | $2.01M | $2.11M | $2.86M | 98.2% | +1539.5% |
| Product revenue | $611.00K | $633.00K | $654.00K | $671.00K | 1.8% | -3.5% |
By region
From the segment and revenue-disaggregation notes of Orchestra BioMed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.